Establishment of Criteria and Selectivity Parameters; Staffing of Sunesis FTEs. (a) Promptly following any designation of a Collaboration Target pursuant to this Section 2.5, the Parties shall establish, the definition and scope of such Collaboration Target, as well as any additional Target-specific criteria for a compound to be deemed a Hit Compound or Lead Compound for such Collaboration Target as provided in Section 1.13, provided that the JRC shall not have the authority to amend the Lead Compound Criteria with respect to the threshold affinity levels with respect to such Collaboration Target without the written agreement of the Parties. In addition, in the event that Biogen Idec requests additional FTEs with respect to such Collaboration Target (above those provided for under this Agreement), the Parties shall mutually agree on whether additional Sunesis FTEs shall be funded to conduct activities under the Research Program with respect to such Collaboration Target. (b) In addition to the foregoing, the Parties shall establish the Selectivity Parameters for each Collaboration Target. The Selectivity Parameters for a specific Collaboration Target may be amended after initial designation by the JRC only through mutual written agreement of the Parties. The Selectivity Parameters for all Collaboration Targets shall be set forth in Exhibit 2.5.9 attached hereto; upon request by either Party from time to time, Exhibit 2.5.9 shall be updated to reflect the Selectivity Parameters for the then-current Collaboration Targets. (c) In the event that an Other Biogen Idec Target or a Sunesis Target is designated during the Term of this Agreement, the Parties shall mutually agree on (i) the definition and scope of such Target, and (ii) the Selectivity Parameters for such Target.
Appears in 2 contracts
Sources: Collaboration Agreement (Sunesis Pharmaceuticals Inc), Collaboration Agreement (Sunesis Pharmaceuticals Inc)